A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)

Abstract Patients with ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with dual HER2 blockade than ER−/HER2+ BC. Endocrine therapy plus trastuzumab is effective in advanced ER+/HER2+ BC. Inhibition of CDK4/6 and HER2 results in synergi...

Full description

Bibliographic Details

Published in:	npj Breast Cancer
Main Authors:	Foluso O. Ademuyiwa, Donald W. Northfelt, Tracey O’Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie L. Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S. Hagemann, Michael D. Iglesia, Cynthia X. Ma
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-01-01
Online Access:	https://doi.org/10.1038/s41523-022-00504-z